UCB癫痫症治疗药Keppra静脉注射剂获得了FDA的批准，它是近期在美国获准的唯一一种含口服剂和注射剂的抗痫药。

Keppra用作局部发作性癫痫症成人患者的辅助治疗药。之前，它已具备片剂和口服液两种剂型，刚获准的注射剂将在癫痫症急性发作时使用。

部分中文Keppra静脉注射剂处方资料（仅供参考）

通用名称为注射Keppra，Enbrel作者

左乙拉西坦100mg/mL;稀释后静脉滴注。

法律分类：
接收

Keppra，Enbrel作者注射液制造商
联合银行公司

Keppra，Enbrel作者适应症注射
时使用口服暂不可行的：如在局部发作的辅助以及在青少年肌阵挛性肌阵挛性癫痫患者在发作的辅助治疗。

成人剂量注射Keppra，Enbrel作者
≥16yrs：注入超过15分钟。部分发作：最初500毫克，每天两次;可能增加的1g/day增量在2周的时间间隔，最大3g/day。肌阵挛性：最初500毫克每日两次的1g/day增量在2周的时间间隔增加目标3g/day剂量。肾功能损害：肌酐清除率50-80mL/min：500毫克，1克，每12小时; CrCl为30-50mL/min：250 - 750mg，每12小时肌酐清除率<30mL/min：250 - 500毫克，每12小时;终末期肾病透析患者：500毫克- 1G型每24小时和250 - 500mg的后透析补充。

儿童注射剂量为Keppra，Enbrel作者
<16yrs：不推荐。

另外：
Keppra，Enbrel作者
Keppra，Enbrel作者口服液
XR的Keppra，Enbrel作者

警告/ Keppra，Enbrel作者注射的注意事项
肾功能损害。自杀倾向（监视器）。避免突然停止。老人（考虑监测肾功能）。劳动和交付。妊娠（Cat.C）。哺乳母亲：不推荐。

Keppra，Enbrel作者注射液不良反应的
嗜睡，无力，感染，头晕，协调困难（例如，共济失调，异常步态），情绪和行为异常（如烦躁，愤怒，抑郁，焦虑，冷漠），颈部疼痛，咽炎，血液异常;罕见：精神病症状。孩子们：还意外受伤，敌意，紧张。 XR的：还恶心。

Keppra，Enbrel作者注射须知
注册怀孕患者接触到左乙拉西坦致电（888）537-7734。

Keppra，Enbrel作者注射液是如何提供？
制表250毫克，500毫克，750mg - 120
1000毫克- 60
的XR - 60
溶液铂
单用小瓶（5毫升）-10

---------------------------------------------------------------
原产地英文商品名:
KEPPRA 500mg/5ml/vial 10vials/box
原产地英文药品名:
LEVETIRACETAM
中文参考商品译名:
开浦兰 500毫克/5毫升/瓶 10瓶/盒
中文参考药品译名:
左乙拉西坦
生产厂家中文参考译名:
UCB制药公司
生产厂家英文名:
UCB pharmaceutical corporation

---------------------------------------------------------------

KEPPRA is an antiepileptic drug available as 250 mg (blue), 500 mg (yellow), 750 mg (orange), and 1000 mg (white) tablets and as a clear, colorless, grape-flavored liquid (100 mg/mL) for oral administration.

The chemical name of levetiracetam, a single enantiomer, is (-)-(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide, its molecular formula is C8H14N2O2 and its molecular weight is 170.21. Levetiracetam is chemically unrelated to existing antiepileptic drugs (AEDs).

Levetiracetam is a white to off-white crystalline powder with a faint odor and a bitter taste. It is very soluble in water (104.0 g/100 mL). It is freely soluble in chloroform (65.3 g/100 mL) and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane. (Solubility limits are expressed as g/100 mL solvent.)

KEPPRA tablets contain the labeled amount of levetiracetam. Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, polyethylene glycol 3350, polyethylene glycol 6000, polyvinyl alcohol, talc, titanium dioxide, and additional agents listed below:
250 mg tablets: FD&C Blue #2/indigo carmine aluminum lake
500 mg tablets: iron oxide yellow
750 mg tablets: FD&C yellow #6/sunset yellow FCF aluminum lake, iron oxide red

KEPPRA oral solution contains 100 mg of levetiracetam per mL. Inactive ingredients: ammonium glycyrrhizinate, citric acid monohydrate, glycerin, maltitol solution, methylparaben, potassium acesulfame, propylparaben, purified water, sodium citrate dihydrate and natural and artificial flavor.

INDICATIONS
KEPPRA is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.

KEPPRA is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.

KEPPRA is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.

DOSAGE AND ADMINISTRATION
KEPPRA is indicated a s adjunctive treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.

KEPPRA is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.

KEPPRA is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.

Partial Onset Seizures
Adults 16 Years And Older
In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing, were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose (see Clinical Studies), a consistent increase in response with increased dose has not been shown.

Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

Pediatric Patients Ages 4 To < 16 Years
Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg BID). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg BID). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 52 mg/kg. Patients with body weight ≤ 20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution. Table 15 below provides a guideline for tablet dosing based on weight during titration to 60 mg/kg/day. Only whole tablets should be administered.
KEPPRA is given orally with or without food.

HOW SUPPLIED
KEPPRA 250 mg tablets are blue, oblong-shaped, scored, film-coated tablets debossed with "ucb 250" on one side. They are supplied in white HDPE bottles containing 120 tablets (NDC 50474- 594-40).
KEPPRA 500 mg tablets are yellow, oblong-shaped, scored, film-coated tablets debossed with "ucb 500" on one side. They are supplied in white HDPE bottles containing 120 tablets (NDC 50474-595-40).
KEPPRA 750 mg tablets are orange, oblong-shaped, scored, film-coated tablets debossed with "ucb 750" on one side. They are supplied in white HDPE bottles containing 120 tablets (NDC 50474-596-40).
KEPPRA 1000 mg tablets are white, oblong-shaped, scored, film-coated tablets debossed with “ucb 1000” on one side. They are supplied in white HDPE bottles containing 60 tablets (NDC 50474-597-66).
KEPPRA 100 mg/mL oral solution is a clear, colorless, grape-flavored liquid. It is supplied in 16 fl. oz. white HDPE bottles (NDC 50474-001-48).

Storage
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].